Skip to main content
SpringerLink
Log in

The biotechnology bubble machine

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. The Biotech Advisor (Charter Financial Publishing Network, Shrewsbury, NJ, 2002).

  2. Ackerman, J. A promise unfulfilled in biotechnology: decline and fall of Alpha-Beta speaks volumes about pitballs of industry. The Boston Globe, February 10 (1999).

    Google Scholar 

  3. Leonhardt, D. Northeast Quietly Becomes a Health Care Corridor. New York Times, December 30 (2002).

  4. http://www.bio.org/news/stats.asp

  5. Lähteenmäki, R. & Fletcher, L. Nat. Biotechnol. 21, 551–555 (2002).

    Article  Google Scholar 

  6. Feldbaum, C.B., Convergence: Ernst & Young's Biotechnology Industry Report, Millennium Edition (E&Y, New York, 2000).

  7. http://www.bio.org/er/approveddrugs.asp

  8. Lee, K.L., et al. Ann. Intern. Med. 120, 876–885 (1994).

    Article  CAS  Google Scholar 

  9. Federal Trade Commission. Resolving Anticompetitive Concerns, FTC Clears $16 Billion Acquisition of Immunex Corp. by Amgen Inc. (FTC, Washington, DC, 2002).

Download references

Author information

Authors and Affiliations

  1. chief science officer of Boveran, San Ramon, CA

    David Rasnick

Authors
  1. David Rasnick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rasnick, D. The biotechnology bubble machine. Nat Biotechnol 21, 355–356 (2003). https://doi.org/10.1038/nbt0403-355

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0403-355

  • Springer Nature America, Inc.

Search

Navigation